相关实验视频

Updated: May 29, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

在HR+/HER2-转移性乳腺癌中进行PTEN测试的下一代测序

Nicola Fusco¹, Umberto Malapelle²

¹Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Italy.

Critical reviews in oncology/hematology

|February 5, 2025

概括

对PIK3CA,AKT1和PTEN变化的精确分子测试对于激素受体阳性,HER2-阴性转移性乳腺癌 (MBC) 至关重要. 下一代测序 (NGS) 提供了全面的PI3K通路分析,指导向治疗决策.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
分子诊断学分子诊断学

背景情况:

酸3-激酶 (PI3K) 途径中的分子变化是激素受体阳性,HER2-阴性 (HR+/HER2-) 转移性乳腺癌 (MBC) 的关键驱动因素.
针对这些基因组变化的有针对性的疗法存在,但获得依赖于PIK3CA,AKT1和PTEN的精确分子测试.
下一代测序 (NGS) 是分析这些PI3K路径变化的关键诊断进步.

关键词:

激素受体阳性的乳腺癌下一代测序 (NGS) 是指下一代的测序.通过 PIK3CA 途径.PTEN的修改 PTEN的修改精确瘤学是一门精确的专业.

更多相关视频

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频